Is Suraksha Diagno. overvalued or undervalued?

As of 13 October 2025, the valuation grade for Suraksha Diagnostics has moved from expensive to fair. The company appears to be fairly valued at this time. Key ratios include a PE Ratio of 44.68, an EV to EBITDA of 17.97, and a ROCE of 23.40%.
In comparison to its peers, Suraksha Diagnostics has a PE Ratio that is significantly lower than Max Healthcare, which stands at 92.33, and Apollo Hospitals at 70.2, indicating that Suraksha may offer better value relative to these competitors. While the stock has underperformed against the Sensex over the past year, with a year-to-date return of -23.63% compared to the Sensex's 5.36%, the current valuation suggests that it is not overvalued, especially when considering its strong return metrics.